What type of drug does the targeted drug sotoraxib belong to?

Sotorasib is a targeted drug that is a KRAS G12C inhibitor and is used to treat non-small cell lung cancer (NSCLC) with KRAS G12C mutations. KRASgene mutations are an important factor leading to the development of many cancers, especially in lung cancer. About 13% to 15% of non-small cell lung cancer patients have KRAS G12C mutations. Sotorasiib inhibits the activity of KRAS G12C mutated protein, thus preventing the growth and spread of cancer cells, becoming a new hope for the treatment of this type of lung cancer.

Different from traditional chemotherapy drugs, sotoraxib is a targeted therapy drug that directly targets specific molecular targets in cancer cells. In cancer cells with the KRAS G12C mutation, the KRAS protein plays a key role, leading to excessive cell proliferation. Sotoracib binds to KRAS G12C mutated protein and inhibits its activity, thereby reducing the proliferation of cancer cells and delaying or stopping tumor growth. The targeted therapeutic mechanism of sotoracib makes it an important clinical treatment option for patients with KRAS G12C mutations.

Currently, sotoracib is mainly used to treat KRAS G12C mutation-positive non-small cell lung cancer patients, especially those who have received multiple prior treatments but still have disease progression. Clinical trials have shown that sotoraxib can effectively control tumor growth and significantly extend patients' progression-free survival (PFS). In addition, sotoracib also shows relatively good safety. Common side effects include fatigue, diarrhea, nausea, etc., and most patients can tolerate these side effects.

As a targeted drug, sotorasiib has the advantage of targeting specific gene mutations and reducing its impact on normal cells, thereby avoiding the extensive toxic and side effects caused by traditional chemotherapy. Although the efficacy of this drug has been verified in multiple clinical trials, it is very important for patients to conduct KRAS G12C mutation testing before using this drug. Sotoraxib will be an effective treatment option only if the patient's lung cancer harbors the KRAS G12C mutation. Therefore, accurate genetic testing is an indispensable part of targeted therapy.

Reference materials:https://www.lumakras.com/